KIF5B and adenocarcinoma: These and 28 other mutations were detected at a significantly higher prevalence in adenocarcinoma cases including therapy-associated MET exon 14 skipping mutations (3.8% vs 0.8%), EML4-ALK fusions (2% vs 0%), and KIF5B-RET fusions (0.5% vs 0.1%) (Supplementary Table S2).